MorphoSys AG
Lena-Christ-Strasse 48
Martinsried
Munich
82152
Germany
Tel: 49-0-89-899-27-0
Fax: 49-0-89-899-27-222
Website: http://www.morphosys.com/
Email: info@morphosys.com
560 articles about MorphoSys AG
-
MorphoSys is having a busy week after entering into an equity participation agreement with HIBio and a supply agreement and clinical collaboration with Pfizer and Incyte.
-
MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.
-
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
6/14/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), announced today that the companies entered into an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody.
-
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
6/13/2022
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi ® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47.
-
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
6/10/2022
MorphoSys AG is presenting data from multiple analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a rare bone marrow cancer for which only limited treatment options are available.
-
MorphoSys AG Reports Outcome of Annual General Meeting 2022
5/18/2022
MorphoSys AG announced that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General Meeting which took place on Wednesday, May 18, 2022.
-
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
5/12/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that new data on pelabresib and tafasitamab, marketed in the U.S. as Monjuvi® and in Europe as Minjuvi®, will be presented during the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022) in Chicago from June 3 – 7, 2022 and the 2022 European Hematology Association Hybrid Congress (EHA 2022) in Vienna, Austria, from June 9 – 12, 2022.
-
MorphoSys AG Reports First Quarter 2022 Financial Results
5/4/2022
Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth.
-
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
4/28/2022
MorphoSys AG will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST.
-
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
3/22/2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/16/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021.
-
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
3/15/2022
MorphoSys U.S. Inc. announced that the National Comprehensive Cancer Network Clinical Practice Guidelines ) in Oncology for B-cell Lymphomas have been updated, and the designation for Monjuvi in combination with lenalidomide is now a Preferred Regimen for second-line therapy in patients with Diffuse Large B-cell Lymphoma who are not candidates for transplant.
-
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
-
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
3/10/2022
MorphoSys AG ; will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET.
-
MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
3/10/2022
MorphoSys AG announces that it will account for a non-cash impairment charge on goodwill in the amount of approximately € 231 million.
-
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
1/18/2022
MorphoSys AG reported preliminary Monjuvi U.S. net product sales for the full year of 2021 and provided financial guidance for 2022.
-
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
1/10/2022
MorphoSys AG, announced that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at 5:15 p.m. EST.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
12/11/2021
MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma.
-
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.